Chinese biotech firm Clover says its vaccine is effective against multiple coronavirus variants

Clover Biopharmaceuticals, a Chinese biotech start-up that has developed a protein-based Covid-19 vaccine and is a supplier of Covax, said on Wednesday that trials showed the vaccine was 79 per cent effective against any severity of Covid-19 caused by the Delta variant.

The study also showed the vaccine candidate, known as SCB-2019, was 92 per cent effective against the Gamma variant and 59 per cent against the Mu variant. The overall efficacy against all the strains in the study – including the three variants, which comprised 73 per cent of the total – was 67 per cent, according to a statement released by Clover.